Indegene Announces Strategic Collaboration with Microsoft to Help Life Sciences Companies Scale Up Generative AI Adoption and Accelerate Business Impact

Bengaluru, July 11, 2024: Indegene today announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, thereby driving faster innovation at scale.
 
Indegene and Microsoft have committed to developing resources in highly specialized and skilled medical and technology tools to co-innovate generative AI services and workflows across commercial, medical, regulatory, and clinical functions. 
 
“GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we’re closely working with many of our clients to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage”, said Tarun Mathur, CTO, Indegene. “As we double down on efforts to strengthen our innovation prowess, we will keep exploring opportunities for greater collaboration with key technology providers. We remain focused on helping our clients harness the potential of GenAI with targeted solutions to address some of their most pressing operational challenges and make their business future-ready.”
 
Alok Lall, Chief Operating Officer, Microsoft India & South Asia, said, “Generative AI is profoundly shaping every industry, including life sciences, by offering unprecedented avenues for healthcare technology advancements. According to a Microsoft-commissioned study conducted by IDC[i], a staggering 79% of healthcare organizations have now embraced AI. This demonstrates that the tangible business value of this transformation is indisputable. By seamlessly integrating Indegene's domain knowledge with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand at the forefront of advancing generative AI within the life sciences sector. This collaborative effort empowers life sciences companies to fully harness AI's capabilities, fostering innovation and scalability within the industry.”